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Abstract
Neoplasms of central nervous system accounts for approximately 1% of tumors of the 
human body, and they can be primary or secondary (metastatic), benign or malignant, 
and intra-axial or extra-axial. This chapter includes some most common brain and spi-
nal cord tumors, like pituitary adenomas, meningiomas and gliomas, with their clinical, 
imaging, and histological characteristics for the diagnosis purpose, with additional treat-
ment options and prognosis.
Keywords: brain tumors, central nervous system (CNS), World Health Organization 
(WHO), WHO grades, pituitary adenomas, meningiomas, gliomas, diffuse astrocytoma 
(WHO grade II), anaplastic astrocytoma (WHO grade III), glioblastoma (WHO 
grade IV), oligodendroglioma (WHO grade II), anaplastic oligodendroglioma (WHO 
grade III), magnetic resonance imaging (MRI), computerized tomography (CT), 
immunohistochemical stain (IHC), isocitrate dehydrogenase-1 (IDH-1), fluorescent 
in situ hybridization (FISH), chromosome 1p/19q co-deletion, MGMT, molecular 
diagnosis, neuroimaging study, dural tail
1. Introduction
Human central nervous system (CNS) is composed of brain and spinal cord and their covers. 
The neoplasms of human CNS account for about 1% of all human body tumors. Location is 
important information for making diagnosis of brain tumors. Generally speaking, the tumor 
of the CNS are divided into two large categories: intro-axial and extra-axial tumors; intro-axial 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
tumors mean those tumors that arise from the brain/spinal cord parenchyma, such as astrocy-
tomas and glioblastomas while extra-axial tumors indicate those tumors that originate from the 
covers or nerve roots of brain/spinal cord, such as meningiomas and schwannomas (Figure 1). 
We include in this chapter only a few most common brain tumors [1].
Tumors of CNS include benign and malignant tumors, based on the World Health Organization 
(WHO) classification, brain tumors have four grades, from grade I to IV. Grade I tumor is true 
benign one, like pilocytic astrocytomas in children, with partial or complete surgical resec-
tion, the tumor will be cured. Grade II tumors are low-grade malignant potential with both 
recurrent tendency and progression to higher-grade tumor even after being completely sur-
gically removed. Grade III is high-grade malignant tumor, it not only can be progressing to 
higher-grade tumor but also has greater recurrent potential, while the grade IV tumor is very 
high-grade malignant tumor, such as glioblastoma (GBM), even with current combined sur-
gical, radiation and chemotherapies, patients’ expected survival time is only approximately 
22–24 months [1].
2. Pituitary adenomas
The anterior pituitary gland (adenohypophysis) is an important organ for human develop-
ment and physiological functions, which comprises several different cell types, responsible 
for the synthesis and secretion of a specific hormone or group of specific hormone (plurihor-
monal), such as growth hormone (GH), adrenocorticotropic hormone (ACTH), and prolactin 
(PRL). Each of these cell types may give rise to a discrete pituitary adenoma subtype that is 
either hormonal active (functional) or inactive (nonfunctional).
As one of the most common pituitary neuroendocrine tumors, pituitary adenomas constitute 
the overwhelming majority of tumors arising in the pituitary gland and accounts for 10–15% of 
intracranial neoplasms. Incidental microadenoma (smaller than 10 mm in diameter) may occur 
in up to 27% of pituitary glands examined at autopsy and up to one-fifth of the population has 
Figure 1. A well-defined right temporal intra-axial hyperintense lesion on FLAIR, see arrow (a); a heterogeneous extra-
axial mass at left cerebellopontine angle (CPA) with internal auditory meatus extension on post-contrast T1WI, see arrow 
(B), is classic for Schwannoma/acoustic neuroma.
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a pituitary abnormality on magnetic resonance imaging (MRI) [10]. The monoclonal nature of 
the majority of pituitary adenoma subtypes was supported by data from LOH (loss of heterozy-
gosity) analysis and by X-chromosomal inactivation analysis in female patients. Which strongly 
suggests the view that pituitary adenomas result from a clonal expansion of a single mutated 
pituitary cell [10] (Figure 3).
2.1. Clinical features
The clinical manifestations of pituitary adenomas can be divided into two categories: The 
first is the endocrine functional changes caused by pituitary adenoma; the second is the local 
space-occupational effect caused by tumors. They can also invade downwards into the para-
nasal sinus, laterally into the cavernous sinus (to compress cranial nerves leading to ophthal-
moplegias) and upwards into the brain parenchyma (Figure 2). Endocrine changes include 
amenorrhea, lactation, obesity, acromegaly and gigantism, and hypopituitarism, and so on 
[10]. By testing six types of hormones secreted by the pituitary gland, functional pituitary ade-
noma can be detected. For example, among adult pituitary adenomas, PRL producing adeno-
mas are the most common hormone-secreting tumors, in which the elevated serum prolactin 
(prolactinemia) level may be helpful for diagnosis. While nonfunctional pituitary adenomas 
are often found late and are often found when secondary symptoms of compressing adjacent 
surrounding tissue becomes apparent, which includes visual field defects, especially the tem-
poral visual field defects, blindness by compressing optic chiasm, and headache, and so on. 
While the majority of pituitary tumors are nonmetastasizing and slowly growing adenomas, 
some cases (the proportion is low, but the exact percentage is unknown) will become invasive 
and a very small portion (approximately 0.1%) will become malignant [9]. Add more growth 
pattern in different directions.
2.2. Radiologic finding
Pituitary adenomas are characterized by CT low-density occupying lesions on pituitary or 
MRI (T1WI) low-signal occupying images (Figure 1). Contrast enhanced CT and MRI can 
Figure 2. MRI sagittal T1 W1 shows this enhanced mass of giant pituitary adenoma, see arrow (a). MRI shows occupied 
masses in both sellar region and cerebellum, see arrows, based on the patients’ history, the lesions most likely a pituitary 
carcinoma with metastasis to cerebellum (B).
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significantly improve the display and diagnostic rates of pituitary adenomas, especially 
microadenoma. The pituitary microadenoma with diameter less than 10 mm has little effect 
on the surrounding bone tissue around the sellar region; however, pituitary adenomas 
with diameter larger than 10 mm (often referred to as macroadenomas) often result in 
enlargement of the sellar region and even destruction of the surrounding sphenoid bone 
(Figure 2). Pituitary adenomas with destructive behavior are often diagnosed as invasive 
pituitary adenomas by radiology experts [10].
2.3. Microscopic finding and diagnosis
The majority of pituitary adenomas are composed of monotonous anterior pituitary gland 
cells in similar size and shape with abundant small vessels and variant amount of cyto-
plasm (Figure 3). Compared with the normal histology of the pituitary gland, the reticular 
fibers in pituitary adenomas are significantly reduced, so the reticulin stain can also be 
helpful to differentiate pituitary adenoma from pituitary hyperplasia, the latter shows only 
expansion rather than rupture of pituitary acini demonstrated by reticulin stain. The mono-
clonal nature of the majority of pituitary adenoma subtypes was supported by finding that 
the tumor cells have the similar morphology (Figure 3). The pituitary adenoma subtypes 
secreting different hormone subtypes are slightly different in morphology and also differ in 
clinical biological behavior.
2.4. Immunohistochemical findings
A minimal panel of immunostains is helpful for the diagnosis of pituitary adenomas, which 
includes synaptophysin and low-molecular weight cytokeratin CAM 5.2. Pituitary adenomas, as 
most neuroendocrine tumors, are uniformly immunoreactive for synaptophysin (Figure 4) and 
variably for chromogranin A (another neuroendocrine marker) and CAM 5.2. In addition, syn-
aptophysin immunohistochemically positive in a finely fibrillary pattern even highlights small 
fragments of posterior pituitary gland that can be also sometimes included in the specimen, 
especially in specimens being assessed for Rathke’s cleft cyst.
In terms of specific anterior pituitary hormones necessary for subtyping pituitary adenomas, 
FSH, LH, TSH, ACTH, GH, and PRL (Figure 4) as a small group is highly recommended [7, 8]. 
Figure 3. Monotonous tumor cells in size and shape with abundant small vessels in pituitary adenoma on H&E section 
(a) (H&E stain ×100), and smear (B) (H&E stain ×200).
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In recent 2017 WHO classification, a major technique for tumor classification is the immuno-
histochemical stain, with the combination of immunostains for the main pituitary hormones 
(GH, PRL, ACTH, β-TSH, β-LH, β-FSH, and α-subunit of glycoproteins) in order to deter-
mine the tumor cell’s linage. In some conditions, if the immunohistochemical staining result 
is inconclusive, immunostains for the pituitary transcription factors (PIT-1, SF-1, T-PIT) may 
be necessary. In addition, immunohistochemical stains can be used for the subclassification of 
adenomas variants. For example, low-molecular-weight cytokeratin is very helpful in identify-
ing fibrous bodies in sparsely granulated somatotroph and in acidophilic stem cell adenomas; 
cytokeratin also highlights corticotroph cell differentiation and Crooke’s hyaline changes. With 
the combination of morphology and immunohistochemical markers, there is minimal need for 
ultrastructural analysis (electron microscopic) for the classification of the adenomas [9].
According to the 2017 WHO classification of tumors of the pituitary gland, Table 1 summa-
rizes how these pituitary neuroendocrine tumors are separated according to their clinical 
behavior. A large proportion of tumors are the adenomas (typical) that show low probability 
for recurrence. At the other extreme are the pituitary carcinomas, malignant tumors that by 
definition already have metastasis when diagnosed. Several tumors have higher probability 
Figure 4. Tumor cells of this pituitary adenoma are immunoreactive for PRL (a), and synaptophysin (B) (immuno-
histochemical stains ×100 (brown color indicates positive stain)).
Low probability for 
recurrence
High probability for recurrence Malignant (metastatic) tumor
Pituitary adenoma Adenomas with elevated proliferative activity Pituitary carcinoma
Special subtypes (variants) of adenomas:
Sparsely granulated somatotroph adenoma
Lactotroph adenoma in men
Silent corticotroph adenoma
Crooke cell adenoma
Plurihormonal PIT-1 positive adenoma
Table 1. Likelihood of recurrence of pituitary neuroendocrine tumors.
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Figure 5. This picture shows the tumor from cerebellar mass of Figure 1B as a metastatic pituitary carcinoma, the tumor 
cells show larger nuclei with prominent nucleoli (arrow), indicating its malignancy (H&E stain ×400).
for recurrence than the typical adenomas including adenomas with elevated proliferative 
activity and the special variants of adenomas previously mentioned [9].
In some pituitary adenomas, prominent cellular atypia can be observed but which is not indicative 
of malignancy. To date, there is no definitive morphological index and marker for malignant pitu-
itary adenoma, which is consistent with endocrine tumors in other organs. Pituitary carcinoma 
(Figure 5) can be diagnosed only after a definitive metastasis of pituitary adenoma is identified [9]. 
Atypical pituitary adenomas with biological behavior between pituitary adenomas and pituitary 
carcinomas were abolished in the recent 2017 WHO classification of pituitary adenomas [9], the 
reason is that the exact diagnosis of atypical pituitary adenoma is difficult to be unified and quan-
tified (the cutoff of Ki-67 varies in different studies). According to previous studies, the positive 
rate of Ki-67 and the mutation of P53 tumor suppressor gene are closely related to the invasiveness 
of pituitary adenomas. Ki-67 and P53 (Figure 6) may be an important marker for evaluating the 
risk of recurrence and invasiveness of pituitary adenomas. Many indicators have been included in 
the study of pituitary adenomas, such as GSP (G proteins super-family), ras, and PTTG (Pituitary 
Tumor Transforming Gene), CCND1 (cyclin D1 gene), MEN1, Rb (Retinoblastoma susceptibility 
gene), p16/CDKN2A (the cyclin-dependent kinase inhibitor p16), p27/Kip1, and so on, but now it 
seems to be of limited clinical significance. Attempts at identifying potential aggressive adenomas 
should be made on an individual basis by considering the histology, mitotic index, Ki-67 label-
ing index, and tumor invasiveness [9]. Furthermore, recognition of adenoma variants that have 
intrinsic substantial risk for recurrence and poor clinical behavior is imperative [9]. Therefore, 
more research in order to find a reliable and accurate biomarker reflecting biological behavior of 
pituitary adenomas will be our future goal.
2.5. Treatment for pituitary adenomas
Nonfunctional pituitary macroadenomas are typically managed with transphenoidal surgical 
resection followed by radiation. With the exception of prolactinomas, functional pituitary mac-
roadenomas require surgical resection via a transphenoidal approach with subsequent radio-
therapy, and some patients may also benefit from medical therapy in the postoperative period 
depending on the specific type of adenoma. After surgical resection and radiation therapy of 
growth hormone secreting pituitary adenomas, octreotide is often administered to suppress 
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growth hormone secretion given that lower postoperative growth hormone levels correlate with 
a greater probability of remission after radiotherapy. Corticotropin secreting pituitary adeno-
mas undergo surgery and radiotherapy, but medical therapy is only utilized in patients who 
fail or decline therapy; central or peripherally acting agents are available for use. Gonadotropin 
secreting macroadenomas are also treated with surgical resection and subsequent radiation, 
but medical therapy such as bromocriptine or octreotide are only administered to patients who 
deny surgery or radiation. Thyrotropin secreting macroadenomas respond well to octreotide 
after surgery and radiation and thus can be a useful adjuvant therapy [13–16].
3. Astrocytic and oligodendroglial neoplasms
Taken together, these neoplasms are also referred to as “gliomas”, which are the most common 
intro-axial tumors of the central nerve system (CNS). The current classification of these tumors 
is primarily based on the World Health Organization (WHO) classification which is continually 
updated and internationally accepted [1].
Based on the WHO classification, the gliomas are divided into astrocytomas, oligodendro-
gliomas, and mixed oligoastrocytomas, and includes the criteria for grading of each tumor 
from grade II to grade IV, the highest-grade IV tumor as glioblastomas (GBM). The low-grade 
tumor, although only grade II, due to the diffusely infiltrating nature of the tumor, and their 
strong tendency toward progression and upgrading, with destruction of the normal brain 
architecture, the prognosis of those tumors are poor and post a great challenge to the diag-
nostic pathologists and oncologists.
4. Diffuse astrocytomas (WHO grade II)
4.1. Definition
The WHO grade II diffuse astrocytoma is a well-differentiated, diffusely infiltrative neoplasm 
[1, 2].
Figure 6. High expression of Ki-67 proliferation index in tumor cells (a) and approximately 30% of tumor cells express mutant 
P53 protein by nuclear stain (B), both suggesting an aggressive behavior of this tumor (immunohistochemical stains ×200).
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4.2. Clinical features
Diffuse astrocytomas most frequently affect the cerebral hemisphere of young to mid-age adult 
patients and the brainstem and thalamus of children. Occasionally, the tumors also occur in the 
cerebellum or spinal cord. Those better circumscribed (non-infiltrating) astrocytomas should be 
distinguished from diffuse astrocytomas, since the latter carries much worse prognosis [17–24].
Diffuse astrocytomas may produce nonspecific symptoms of mass effect, seizures, and neuro-
logic deficits according to the lesions’ size and location, and rate of growth. Seizures are more 
common than functional deficits due to cerebral parenchymal destruction, which occur more 
often in highest-grade tumors. Brainstem astrocytomas produce neurologic signs caused by 
dysfunction of cranial nerve nuclei and compression of the sensorimotor tracts that traverse 
the pons and medulla [2].
The infiltrating and diffuse forms of astrocytoma occur throughout the CNS, primarily affect-
ing adult patients and mostly involving the cerebral hemispheres. Hypercellularity with 
nuclear atypia are key points for diagnosis, although mitosis is rarely identified, and necrosis 
and vascular proliferation should not be observed in this tumor. The tumor can progress to 
higher grade, like anaplastic astrocytoma (WHO grade III), and even glioblastomas (WHO 
grade IV). The infiltrating nature of the tumor makes completely surgical resection without 
damaging the functional cerebral area almost impossible and its resistance to conventional 
therapy making this type of tumor a medical challenge.
4.3. Radiologic finding
By magnetic resonance imaging (MRI), diffuse astrocytomas (grade II) are present as ill-
defined areas of low signal intensity on T1-weighted images. Due to their content of bright 
edema fluid, they are even more obvious on T2-weighted or fluid-attenuated inversion recov-
ery (FLAIR) images (Figure 1A). Contract enhancing should not be observed in grade II dif-
fuse astrocytomas [2].
4.4. Microscopic finding
Hypercellularity and nuclear atypia are the important diagnostic features for grade II diffuse 
astrocytomas. Those lesions are primarily located in white matter. The tumor cells widely 
infiltrate the gray matter. The margin of such tumors is indistinct since tumor cells lie individ-
ually dispersed within intact parenchyma and often follow fiber pathways for some distance. 
Such tumor spread is often more apparent in anaplastic astrocytoma (grade III) or glioblas-
toma (grade IV). Astrocytomas often infiltrate the overlying cerebral cortex or deep hemi-
spheric structures. The so-called “secondary structures of Scherer” indicate the proliferation 
of tumor cells in subpial, perivascular, perineuronal, and subependymal zones. Such charac-
teristic changes are usually more prominent in oligodendrogliomas, astrocytomas undergo-
ing anaplastic transformation, or in gliomatosis cerebri [1, 2].
In addition to hypercellularity, almost all astrocytomas possess cells with enlarged, cigar-
shaped, irregular and hyperchromatic nuclei. Prominent nucleoli are uncommon in grade II 
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diffuse astrocytomas. As well, mitosis, especially multiple mitoses, should not be observed in 
most classic grade II diffuse astrocytomas [2].
The cytoplasm of astrocytoma cells varies considerably both in amount and configuration. 
In some cases, the tumor cells’ fibril-free cytoplasm is scant and devoid of processes, making 
it a feature of “naked nuclei”, in some other cases, the tumor cells have varying quantities 
of fibril-containing cytoplasm and short, often asymmetric processes, which is the basis of 
the overtly astrocytic nature of this tumor [2]. Gemistocytes (fat astrocytes) occur in varying 
numbers, and only a few astrocytomas have enough glassy cytoplasm to justify the term gem-
istocytic astrocytoma. Most tumor cells in gemistocytic astrocytoma show a plump, glassy 
cell body and an eccentric corona of short, stout-to-delicate processes. Such cells, when scat-
tered and well differentiated, can mimic reactive astrocytes. For reactive changes, the main 
features are their uniform distribution, minimal increase in number, and symmetric stellate 
configuration of long-radiating processes. Such cells are best seen in smear preparations or on 
immunostains for glial fibrillary acidic protein (GFAP).
It is important to know that most gemistocytic tumors fall into the category of anaplastic 
astrocytoma, or into the highest grade, glioblastoma, when microvascular proliferation and/or 
necrosis are present (see below).
Most low-grade tumor and reactive changes may contain microcysts and microcalcification, 
suggesting a long-term process, which are helpful features for making our diagnosis.
4.5. Immunohistochemical findings
Almost all diffuse astrocytomas are both S-100 protein and vimentin protein reactive; the 
tumor cells cytoplasm often is immunoreactive for GFAP. In gemistocytic tumors, GFAP reac-
tivity is usually more prominent at the periphery of the cells. Staining for p53 protein is vari-
able in diffuse astrocytomas; nuclei are diffusely immunoreactive in approximately one-third 
of tumors [1, 2].
MIB-1 (Ki67) labeling indices of grade II astrocytoma have generally been less than 2%, often 
even 1% or less, but there is considerable case-to-case and region-to-region variation.
Immunostains for mutated p53 protein, together with mutated IDH-1 (isocitrate dehydroge-
nases-1, R132) are used by some people as confirmative markers for the diagnosis of glioma, 
since both genes and their proteins are involved in the tumorigenesis of gliomas by current 
understanding (Figures 7 and 8).
4.6. Differential diagnosis
The most important differential diagnosis of glioma is reactive gliosis or reactive changes, which 
may occur in many conditions, such as infarct, infection, and demyelinative disease. Those 
lesions sometimes can mimic gliomas on imaging study and mistake pathologic diagnosis may 
result in unnecessary treatment for the patients and even more severe damage to patients may 
occur. So the diagnosis of glioma should be made cautiously with more supporting evidence 
ready before making the final diagnosis [2].
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Figure 8. The tumor cells are immunoreactive for GFAP (glial fibrillary acidic protein) (immunohistochemical stain ×100) 
and p53 (immunohistochemical stain ×400), consistent with WHO grade II diffuse astrocytoma. This tumor is with IDH-1 
mutation (no show).
4.7. Treatment of gliomas
4.7.1. Low-grade gliomas
Low-grade gliomas (WHO grade I and II) are typically managed with a combination of sur-
gery, radiation therapy, and chemotherapy; however, the precise treatment is often individu-
alized depending on the patient at hand.
The management of WHO grade II tumors, such as diffuse astrocytoma and oligodendrogli-
oma, is more variable. In patients presenting with neurologic impairment, immediate surgical 
resection is utilized to relieve symptoms and obtain a definitive diagnosis. Asymptomatic 
patients can elect for surgical resection or choose observation. In patients who opt for careful 
observation, surgical intervention is indicated if tumor growth accelerates, neurologic impair-
ment develops, or if evidence of transformation to a high-grade glioma is detected. Given that 
surgery is often not curative, further postoperative therapy with radiation therapy and/or 
Figure 7. This histologic picture corresponds to the tumor in Figure 1A, with increased cellularity and atypia, but no 
significant mitosis, most likely a low-grade, WHO grade II infiltrating glioma (H&E stain ×400).
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chemotherapy is ultimately needed but the timing will depend on the patient’s prognosis. If 
complete resection is achieved and the molecular characteristics are favorable, postoperative 
therapy is delayed until recurrence is detected during observation. Conversely, immediate 
postsurgical chemoradiation is recommended for patients with poor prognostic factors, such 
as neurological deficits, large tumor size, mass effect, incomplete resection, or advanced age. 
Conventional radiation therapy at a dose of 50–54 Gy is typically chosen for low-grade glio-
mas, whereas the chemotherapy regimen is individualized to the patient. PCV (procarbazine, 
lomustine, and vincristine) and temozolomide are the main regimens, and although no trials 
have compared these directly, temozolomide is being used more frequently due to improved 
patient tolerance and ease of administration; despite this, only PCV has proven survival ben-
efit in a randomized control trial [11].
5. Anaplastic astrocytoma (WHO grade III)
5.1. Definition
Anaplastic astrocytoma is a WHO grade III infiltrating astrocytoma, intermediate between 
grade II diffuse astrocytoma and grade IV glioblastoma [1, 2].
5.2. Clinical features
Generally speaking, anaplastic astrocytomas usually occur one decade later than grade II 
tumors and a decade earlier than glioblastomas. The tumors in cerebral hemisphere occur 
most often in the fifth decade, they also appear occasionally in children [1, 2].
5.3. Radiology findings
Some lesions partially enhance on T1-weighted MRI image following administration of con-
trast agents, but not with the perinecrotic ring (ring enhancing) or “rim” pattern that usually 
typifies glioblastoma [2]. Still, a significant portion of anaplastic astrocytomas show no con-
trast enhancing, which makes the pathological diagnosis more informative and important [2].
5.4. Microscopic findings
Anaplastic astrocytoma has more hypercellularity, nuclear pleomorphism, and hyperchroma-
sia; in addition, the presence of mitosis is an important diagnostic feature for grade anaplastic 
astrocytomas, but lack the necrosis and vascular proliferation, which are the characteristic 
findings in glioblastomas.
5.5. Immunohistochemical findings
The staining pattern of anaplastic astrocytomas should be the same as grade II diffuse astrocy-
tomas, whose tumor cells are immunoreactive for GFAP and S-100 protein. Not surprisingly, 
reported ranges of proliferation index of Ki-67 are quite variable, in the range of 5–10% [2].
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5.6. Differential diagnosis
The same as for the grade II diffuse astrocytomas, the major differential diagnosis for anaplas-
tic astrocytomas are those of reactive type lesions. The misdiagnosis of demyelinative lesion 
as a grade III anaplastic astrocytoma may result in unnecessary and fetal radiation therapy to 
patient, which usually causes a medicolegal issue. In that case, the diagnosis should be made 
on strong evidence-based practice.
6. Gliobalstoma multiform (GBM) (WHO grade IV)
6.1. Definition and general features
Glioblastoma is a highly malignant astrocytic glioma with WHO grade IV that appears to 
arise either de novo (primary GBM) or in transition from lower grade gliomas (diffuse astro-
cytoma or anaplastic astrocytoma, secondary GBM). It typically affects adults and is prefer-
entially located in the cerebral hemispheres. The term of “high grade glioma” is sometimes 
used to describe both anaplastic astrocytoma and glioblastoma. GBM is the most frequent 
brain tumor accounting for approximately 12–15% of all intracranial neoplasms and 60–75% 
of astrocytic tumors. In most European and North American countries, the incidence of 
GBM is in the range of 3–4 new cases per 100,000 populations per year. GBM may manifest 
at any age, but preferentially affects adults, with a peak incidence at between 45 to 75 years 
of age. The male female ratio of GBM patients is 1.26 in USA and 1.28 in Switzerland [1, 2].
6.2. Clinical features
Affecting primarily the cerebral hemispheres of adults and the thalamus and brainstem of chil-
dren, GBM is the most common malignant glioma. It is less likely to occur in the optic nerve and 
cerebellum and uncommon in the spinal cord. Most cases are solitary cerebral hemisphere mass 
lesion, but occasional examples appear radiologically separate and warrant the designation 
multicentric GBM. True multicentricity is difficult to establish, however, even at autopsy [1, 2].
The clinical presentation of patients with GBM are similar to those of patients with better 
differentiated diffuse astrocytomas, although accompanying neurologic deficits are more 
frequent, more abrupt in onset, and more rapid in evolution. Unlike lower grade lesions, 
GBMs are often expansile and edema generating. As a result, they are more likely to produce 
frank neurologic deficits and signs of increased intracranial pressure. Acute hemorrhage pre-
cipitates symptoms in occasional cases. Rapid growth within months or even weeks can be 
observed in MRI studies [2].
6.3. Radiologic findings
On MRI, GBM usually have an enhancing ring or rim in post contrast T1-weighted images 
and a generally broad zone of surrounding edema evident in T2-weighted or FLAIR images. 
The central, hypodense core of the lesion represents tumor necrosis, while the contrast 
enhancing ring is highly cellular neoplasm with abnormal vessels that permeable to contrast 
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agents. The peripheral zone of low attenuation indicates vasogenic edema containing varying 
numbers of isolated infiltrative tumor cells [2].
6.4. Microscopic findings
GBMs are heterogeneous tumors with multiple histological variations, and characterized by 
nuclear pleomorphism (different nuclear size and shape), active mitoses, necrosis, especially 
palisading necrosis and/or vascular proliferation. Most times, GBM have an astrocytic quality 
with small amount of pink cytoplasm, while others may have oligodendroglioma-like struc-
tures with prominent perinuclear halos. Small cell GBM is with monotonous small nuclei with 
or without halos resembling anaplastic oligodendroglioma, while at the other end is the giant 
cell GBM, which composed of numerous multinucleated monstrous giant tumor cells with large 
lipid-rich cytoplasm. The infiltrating tumor cells usually have slightly elongated nuclei [1, 2].
Vascular proliferation is characteristic for GBMs, and takes two forms; the most common 
is forms of globular masses resembling the glomerular tufts of the kidney. Another form of 
vascular hyperplasia has endothelial proliferation since it is intraluminal and consists largely 
of endothelial cells within small to medium-sized vessels. This latter type of endothelial pro-
liferation is less common than glomeruloid proliferation and appears to have a more constant 
correlation with high-grade gliomas and poor prognosis [1, 2].
Necrosis, the second cardinal feature of GBM, takes the form of either large confluent areas 
of parenchymal destruction, including of vasculature, or small, often multiple serpiginous 
foci. On MRI scan, it is the large confluent zone of necrosis that comprises the tumor’s hypo-
tense center. Necrotic areas, particularly small foci, often feature peripheral accumulation of 
somewhat radially oriented cells. Such “pseudopalisading” occurs almost exclusively in high-
grade astrocytomas [1, 2]. Sometimes, that necrosis is associated with small vessel thrombosis.
6.5. Immunohistochemical findings
The immunophenotype of GBM includes reactive for GFAP, and S-100 and vimentin. Reactive 
for vimentin is nonspecific and with no diagnostic significance. In addition, immunoreactive 
for IDH-1 and p53 is suggestive of a slightly better prognosis [1–3].
6.6. Molecular and cytogenetic findings
Currently, the primary GBM is considered associated with EGFR vIII (Epidermal Growth 
Factor Receptor variant III) amplification, which carries a poor prognosis, while the second-
ary GBM is associated with mutations of IDH-1 and p53 genes, which suggests a slightly bet-
ter prognosis due to more sensitive to modern chemotherapy [3].
6.7. Treatment for high-grade gliomas
High-grade gliomas are also initially managed with surgical resection with the goal of gross 
total resection. Adjuvant chemoradiation is always required, and temozolomide (TMZ) with 
concomitant radiotherapy is the current regimen of choice. Patients with high-grade gliomas 
are also encouraged to participate in the clinical trials.
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WHO grade III gliomas, such as anaplastic astrocytoma, will require maximal surgical resec-
tion if feasible followed by adjuvant therapy depending on the tumor type. If the tumor is not 
amenable to resection, open or stereotactic biopsy is indicated to guide subsequent adjuvant 
therapy. Options for adjuvant treatments include temozolomide, PCV (procarbazine, lomus-
tine and vincristine), and fractionated external beam radiation therapy of 60 Gy. The specific 
combination of treatment will vary depending on the prognostic factors that were previously 
discussed for grade II gliomas.
Glioblastoma (WHO grade IV) is initially treated with maximal safe resection for all patients. 
For well-performing patients ≤70 years old, postoperative fractionated external beam radia-
tion of 60 Gy is indicated, whereas hypofractionated radiation therapy at a lower dose should 
be considered for patients >70 years old; concomitant temozolomide should be employed in 
both age groups. In poorly performing patients, monotherapy with adjuvant temozolomide is 
typically utilized instead of subjecting the patient to radiation therapy, but hypofractionated 
radiation therapy at a lower dose schedule is a potential option. For any patient on temozolo-
mide, combination treatment with an antiangiogenic agent such as bevacizumab is an option 
but has not been shown to improve overall survival. Another study demonstrated significant 
efficacy with combination of temozolomide and TTFields [12].
7. Oligodendroglioma and oligoastrocytomas (WHO grade II)
7.1. Definition
Oligodendroglioma is a WHO grade II infiltrating glioma composed at least in part, of cells 
resembling oligodendrocytes [1, 2].
The patients with oligodendrogliomas have a significant better prognosis than those with 
infiltrating astrocytomas of comparable grade. The diagnosis of mixed glioma or oligoastro-
cytoma is largely due to a favorable outcome that will be attributed to the presence of an 
oligodendroglioma component whereas overgrowth of the astrocytic component will be used 
to explain cases that recur rapidly as high-grade astrocytoma [1, 2].
7.2. Clinical features
Olidendrogliomas arise throughout the neuroaxis, but primarily affect adults’ cerebral hemi-
spheres. Manifestations of oligodendroglioma include any of the usual consequence of an 
infiltrating, expanding intracranial neoplasm. Seizures are common at presentation; large 
lesions may produce signs and symptoms of increased intracranial pressure [1, 2].
7.3. Radiologic finding
A large intracranial lesion on MRI, especially when long segments of the cortical ribbon, are 
affected. Oligodendroglioma is especially likely when a band of cortical mineralization undu-
lates in a “gyriform” profile. Calcification is not detected in many small oligodendrogliomas, 
however, grade III lesions are large, and while variably enhancing, generally lack the ring 
profile so typical of glioblastoma [2].
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7.4. Microscopic finding
The tumor cells of olidendroglioma like to infiltrate the cerebral cortex, although not uni-
formly distributed, the tumor cells are attractive to neurons (perineuronal satellitosis) and to 
subpia and perivascular regions.
Oligodendroglioma is characteristic for its histology and cytologic monotony, which means 
the tumor is likely a uniform blueness to the section, and it is confirmed on closer view as 
sameness of nuclear size and shape. Round nuclei with small but prominent nucleoli, in all 
grades, the majority of nuclei are round, especially so in grade II lesions, and somewhat less 
so in intermediate to higher-grade lesions. In contrast to astrocytomas, the chromatin pat-
tern is more open and bland, and there is often a clearly defined, solitary nucleolus. Large 
hyperchromatic nuclei may also be observed but not the generalized nuclear pleomorphism 
in many high-grade infiltrating astrocytomas [2].
Perinuclear halos producing a “Fried-egg” artifact (Figure 9). Oligodendrocytes, whether normal 
or neoplastic, are susceptible to the autolytic imbibition of water, resulting in the production 
of a clear perinuclear halo. Perinuclear halos are not specific findings, since they are present 
in some other tumors, such as clear cell ependymoma and neurocytoma [2].
Microcysts. Particularly common in the cortex, which are filled with protein-like fluid; again it 
is not specific for oligodendrogliomas, and can be observed in some other tumors.
Delicate capillaries disposed in a “Chicken-wire” pattern (Figure 9). Blood vessels in better dif-
ferentiated tumors typically consist of short capillary segments arranged geometrically. This 
arrangement resembles the pattern angulations of “chicken-wire”. It is a “soft” finding with 
little diagnostic use.
Microcalcifications: Many oligodendrogliomas exhibit some degree of calcification within the 
tumor or in surrounding brain tissue. It is mainly introcortical, and the deposition takes the 
form of laminated calcospherites. Vascular walls are often affected in heavily mineralized cases.
7.5. Grading
Accounting to the 2007 WHO system, oligodendrogliomas are generally either grade II or III [1].
Figure 9. “Fried-eggs and chicken wire” are characteristic histology for oligodendrogliomas (H&E stain ×200).
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8. Anaplastic or malignant oligodendrogliomas (WHO grade III)
This cellular tumor is with considerable nuclear hyperchromasia, brisk mitoses, and micro-
vascular proliferation, some with necrosis, but palisading necrosis is usually not seen.
Nuclei of grade III lesions vary with the degree of anaplasia, with those of uniformly round 
for less anaplasia to those of histologically malignant tumor but still obviously oligoden-
droglial due to the roundness (more or less) and prominent nucleoli. Truly anaplastic 
lesions have the nuclear features of high-grade astrocytoma, although they usually retain 
oligodendroglioma-like round cells, at least in small numbers. Mitosis and microvascular 
proliferation/hyperplasia are required features in making diagnosis of WHO grade III ana-
plastic oligodendroglioma [2].
8.1. Immunohistochemical findings
So far, there is no a reliable immunohistochemical marker available that allows the specific 
and sensitive recognition of human oligodendrogliomas. However, the specific molecular 
marker is now available for making the diagnosis of oligodendrogliomas (see below).
The proliferation index of MIB-1 (Ki-67) is in the range of 3 to 5% for grade II oligodendro-
glioma, while the anaplastic oligodendrogliomas have much higher proliferation index by 
immunostaining for Ki67 [2].
8.2. Molecular marker
The loss of chromosome arms 1p and 19q is an established genetic hallmark of oligodendrog-
lial tumors [3–6]. This combined loss is detected in up to 80% of oligodendrogliomas and up 
to 60% in anaplastic oligodendrogliomas, with decreasing frequency in mixed oligoastrocytic 
tumors [6]. The 1p/19q co-deletion has proven its use as both diagnostic and prognostic marker 
Figure 10. The FISH test shows the 1p (red in a) and 19q (red in B) co-deletion in an oligodendroglioma, the green dots 
in the pictures as control.
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for oligodendrogliomas. The tumor with this genetic mutation has a better response to therapy 
and a longer survival time, regardless of using chemotherapy, radiotherapy or the combined 
therapy [4, 5]. Various techniques are available to detect 1p/19q deletion; however, fluorescent 
in situ hybridization (FISH) is often employed due to its technical ease (Figure 10). Another 
frequently utilized method is loss of heterozygosity (LOH), which is a PCR-based test that 
compare tumor DNA to the patients “normal” DNA, usually from peripheral blood [5, 6].
9. Meningiomas
9.1. Definition
A group of mostly benign, slow-growing extra-axial neoplasms that most likely derive from 
the meningothelial cells of the arachnoid layer. People refer to it as “dura-based tumor.” They 
are categorized into three WHO grades (I-III) with more than 15 histologic subtypes [1, 2].
9.2. Clinical features
Meningiomas account for about 36.1% of all primary brain tumors. It is the most frequently 
reported brain tumor in the USA. They are most likely to be found in adults older than 60; the 
incidence appears to increase with age. Rarely are meningiomas found in children, but preg-
nant women carry an increased risk for meningiomas. For brain meningiomas, the incidence 
between male and female is about the same; but for spinal meningioma, it is female patient 
dominant, with primarily psammomatous subtype meningioma (Figure 11) [1, 2].
Meningiomas usually grow slowly and may reach a large size before interfering with the 
normal functions of the brain. The resulting symptoms depend on the location of the tumor 
within the brain. Headache and weakness in an arm or leg are the most common symptoms. 
Figure 11. Left temporal intra-axial hyerintense mass with medial uncal herniation compression of the left midbrain on 
Flair, arrow shows dural tail sign (a). T1WI MRI demonstrates multiple dura-based enhancing mass lesions, most likely 
NF-2 mutated multiple meningioma (B).
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However, seizures, personality changes, and/or visual problems may also occur. Patients 
often have subtle symptoms for a long period before the meningioma is diagnosed [1, 2].
9.3. Radiologic finding
A contrast enhanced CT (computerized tomography) and/or MRI (magnetic resonance imag-
ing) scan could be used. Typically, it appears as extra-axial masses with a broad enhanced 
dural base (“dural tail sign”). Some refer to it as “mouse tail sign”, which is a radiological 
diagnostic marker for meningioma (Figure 12). They are usually homogeneous and well cir-
cumscribed, although many variants are encountered. Peritumoral edema may be seen with 
grade II or III tumors, secretory or adherent microcystic subtype. While MRIs are in some 
ways superior, the CT can be helpful in determining if the tumor invades the bone, or if it’s 
becoming hard like bone [2].
9.4. Microscopic finding
Histologically, meningioma cells are relatively uniform, with a tendency to encircle one 
another, forming meningiothelial whorls and psammoma bodies (laminated calcific concre-
tions). As such, they also have a tendency to calcify and are highly vascularized. There are 
more than 10 histological subtypes of meningiomas associated with different WHO grading 
as listed below [2].
• WHO grade I: 9 subtypes
 ○ Meningothelial meningioma
 ○ Fibrous (fibroblastic) meningioma
 ○ Transitional (mixed) meningioma
 ○ Psammomatous meningioma
 ○ Angiomatous meningioma
 ○ Microcystic meningioma
 ○ Secretory meningioma
 ○ Lymphoplasmacyte-rich meningioma
 ○ Metaplastic meningioma
• WHO grade II: 3 subtypes
 ○ Chordoid meningioma
 ○ Clear cell meningioma
 ○ Atypical meningioma
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• WHO grade III: 3 subtypes
 ○ Papillary meningioma
 ○ Rhabdoid meningioma
 ○ Anaplastic meningioma
As to molecular pathology, between 40 and 80% of meningiomas contain an abnormal chro-
mosome 22. The cause of this abnormality is not known. Meningiomas also frequently have 
extra copies of the platelet-derived growth factor (PDGFR) and epidermal growth factor 
receptors (EGFR), which may contribute to the growth of these tumors. TRAF7 mutations 
are present in about one-fourth of meningiomas. Mutations in the TRAF7, KLF4, AKT1, and 
SMO genes are commonly expressed in benign skull-based meningiomas. Mutations in NF2 
are commonly expressed in meningiomas located in the cerebral and cerebellar hemispheres. 
People with neurofibromatosis type 2 (NF2) have a 50% chance of developing one or more 
meningiomas (Figure 12B) [1].
9.5. Immunohistochemical findings
The vast majority of meningiomas are positive for EMA, progesterone receptor and vimentin 
by immunohistochemical stain. Recently, a new marker somatostatin receptor 2A (SSTR2A) is 
expressed strongly and diffusely in almost all cases of meningiomas [1]. S100 protein positiv-
ity is most common in fibrous meningiomas, but is not usually diffuse, as it is in schwanno-
mas. Other potentially useful immunohistochemical markers in selected cases include Ki-67. 
Studies have suggested that meningiomas with an index of >4% have an increased risk of 
recurrence similar to that of atypical meningioma, whereas those with an index of >20% are 
associated with death rates analogous to those associated with anaplastic meningioma [1, 2].
Figure 12. Meningiothelial whorl (see arrow, H&E stain ×400) (a) and psammoma body (brownish blocks, see arrow, 
H&E stain ×200) (B) are a diagnostic hallmarks for meningioma. (B) Shows a psammomatous type meningioma, it is 
predominantly in female patient with spinal meningiomas.
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9.6. Differential diagnosis
The most important differential diagnosis of meningioma is solitary fibrous tumor/hemangio-
pericytoma (SFT). It was CD34 and STAT6 immunoreactive, which was not seen in meningio-
mas. Others were chordoma, schwannoma, superficial glioblastoma/gliosarcoma and metastatic 
carcinoma, and so on.
Importantly, a so-called collision tumor sometimes occurs between meningioma and meta-
static carcinoma, especially metastatic breast cancer is more likely to spread into meningioma, 
probably due to the presence of progesterone receptor (PR) in meningioma attracts breast can-
cer cells. It is interesting to know that meningiomas not only occur in the system of CNS but 
also occur in other organs, such as lung and bone; even skin meningioma has been reported, 
although the pathogenesis is largely unknown.
9.7. Treatment for meningiomas
The management of meningioma is often guided by tumor size, the presence or absence of 
symptoms, and the WHO grade; as a result, the specific treatment varies from patient to patient. 
Management typically revolves around observation versus surgery and/or radiotherapy, and 
systemic chemotherapy is only considered in cases of malignant tumors, inoperable tumors, or 
exhaustion of other treatments [25–28].
In asymptomatic patients with WHO grade I meningioma less than 3 cm in size and low 
potential for neurologic impairment, observation is recommended; however, if symptomatic 
and amenable to surgery, resection is indicated. Radiotherapy alone is considered for symp-
tomatic patients with meningioma unamenable to surgical resection [25, 26].
Meningiomas greater than 3 cm in size can be observed if asymptomatic, but surgical resec-
tion is also indicated. If the patient chooses surgery, radiotherapy is administered if there is 
subtotal resection of a WHO grade II meningioma or if a grade III meningioma is diagnosed. 
Symptomatic grade II or III meningiomas greater than 3 cm should undergo surgery followed 
by radiotherapy, but if inoperable, radiotherapy alone is employed and the patient is coun-
seled on clinical trials for potential systemic therapy [26–28].
10. Conclusion
In summary, the neoplasms of the CNS are uncommon tumors, accounting for approximately 
1% of tumors in human body. They can be benign or malignant; primary or secondary (meta-
static) by origin; can be extra-axial or intro-axial by locations. Except WHO grade IV glioblas-
tomas, most other CNS tumors can be successfully managed by surgery, chemotherapy and 
radiation therapies. An accurate diagnosis is vitally important not only for treatment options 
but also for prognosis. As more and more genetic information about CNS tumors become 
available, we are optimal to be able to cure those tumors in the near future.
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